FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

Season 7, Episode 31,   Sep 19, 2022, 06:40 PM

Headliner
Share
Subscribe

Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigatinib, and the importance of identifying chromosomal abnormalities in patients with this aggressive disease.

Share
Subscribe
Next
Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders
Top episodes
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air
Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer
by OncLive® On Air